Mechanism-based Combinations with Pim Kinase Inhibitors in Cancer Treatments

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|20|42|6670-6681

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.20, Iss.42, 2014-12, pp. : 6670-6681

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

PIM1 kinase as a target for cancer therapy

By Merkel Anna Lena   Meggers Eric   Ocker Matthias  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 4, 2012-04 ,pp. : 425-436

Informa Healthcare

Access to resources Recommend Favorite

Mechanism-Based Inhibitors from Phytomedicine: Risks of Hepatotoxicity and their Potential Hepatotoxic Substructures

By  

Current Drug Metabolism, Vol. 17, Iss. 10, 2016-12 ,pp. : 971-991

Bentham Science Publishers

Access to resources Recommend Favorite

Fluorinated Mechanism-Based Inhibitors: Common Themes and Recent Developments

By  

Current Topics in Medicinal Chemistry, Vol. 14, Iss. 7, 2014-04 ,pp. : 865-874

Bentham Science Publishers

Access to resources Recommend Favorite

Recent Developments in the Design of Mechanism-based and Alternate Substrate Inhibitors of Serine Proteases

By  

Current Topics in Medicinal Chemistry, Vol. 4, Iss. 12, 2004-08 ,pp. : 1203-1216

Bentham Science Publishers

Access to resources Recommend Favorite

Mammalian Cytosine DNA Methyltransferase Dnmt1: Enzymatic Mechanism, Novel Mechanism-Based Inhibitors, and RNA-directed DNA Methylation

By  

Current Medicinal Chemistry, Vol. 15, Iss. 1, 2008-01 ,pp. : 92-106

Bentham Science Publishers

Access to resources Recommend Favorite